Literature DB >> 14647464

Distinct patterns of microsatellite instability are seen in tumours of the urinary tract.

James W F Catto1, Abdel-Rahmene Azzouzi, Najla Amira, Ishtiaq Rehman, Kenneth M Feeley, Simon S Cross, Gaelle Fromont, Mathilde Sibony, Freddie C Hamdy, Oliver Cussenot, Mark Meuth.   

Abstract

To date, two forms of microsatellite instability (MSI) have been described in human cancer. MSI typical of hereditary nonpolyposis colon cancer (HNPCC), is due to deficient DNA mismatch repair (MMR) and is defined with mono- and dinucleotide repeat microsatellites. A second variety of instability is best seen at selective tetranucleotide repeats (EMAST; elevated microsatellite alterations at select tetranucleotides). While MSI occurs infrequently in bladder cancers, EMAST is common. Sporadic tumours with the largest proportion showing MSI are those found most frequently in HNPCC kindreds. While bladder cancer is not frequently seen in HNPCC, upper urinary tract tumours (UTTs) are. Having previously found a low frequency of MSI in bladder cancer, we sought to determine the relative levels of MSI and EMAST in transitional cell carcinoma (TCC) of the upper and lower urinary tracts. Microsatellite analysis was performed at 10 mono- and dinucleotide and eight tetranucleotide loci, in 89 bladder and 71 UTT TCC. Contrasting patterns of instability were seen in urinary tumours. In bladder cancer, MSI was rare and EMAST was common. The presence of EMAST was not related to tumour grade, stage, subsequent outcome or immunohistochemical expression of the MMR proteins. In UTT, while MSI occurred frequently, EMAST was seen less frequently than in bladder cancer. When TCC of the upper and lower urinary tracts are compared, MSI-H is more frequent in UTT and EMAST more frequent in bladder cancer. Our findings show that, as for colorectal cancer, the pattern of MSI varies with location in the urinary tract. In addition, we have confirmed that MSI and EMAST are discrete forms of MSI, and that the presence of EMAST does not affect tumour phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14647464     DOI: 10.1038/sj.onc.1206964

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  Spectrum of molecular alterations in colorectal, upper urinary tract, endocervical, and renal carcinomas arising in a patient with hereditary non-polyposis colorectal cancer.

Authors:  Pierre Mongiat-Artus; Catherine Miquel; Jean-François Fléjou; Florence Coulet; Jérôme Verine; Olivier Buhard; Hany Soliman; Pierre Teillac; Françoise Praz
Journal:  Virchows Arch       Date:  2006-04-26       Impact factor: 4.064

2.  Colorectal cancer: sailing with a T-cell EMAST.

Authors:  Ajay Goel
Journal:  Dig Dis Sci       Date:  2011-12-20       Impact factor: 3.199

3.  A long AAAG repeat allele in the 5' UTR of the ERR-γ gene is correlated with breast cancer predisposition and drives promoter activity in MCF-7 breast cancer cells.

Authors:  C L Galindo; J F McCormick; V J Bubb; D H Abid Alkadem; Long-Shan Li; L J McIver; A C George; D A Boothman; J P Quinn; M A Skinner; H R Garner
Journal:  Breast Cancer Res Treat       Date:  2010-12-10       Impact factor: 4.872

Review 4.  Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.

Authors:  David R Yates; James W F Catto
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

5.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Authors:  Joaquim Bellmunt; Hans von der Maase; Graham M Mead; Iwona Skoneczna; Maria De Santis; Gedske Daugaard; Andreas Boehle; Christine Chevreau; Luis Paz-Ares; Leslie R Laufman; Eric Winquist; Derek Raghavan; Sandrine Marreaud; Sandra Collette; Richard Sylvester; Ronald de Wit
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

6.  Alterations of microsatellite loci GSN and D18S51 in urinary bladder cancer.

Authors:  S Saidi; Z Popov; S Stavridis; S Panov
Journal:  Hippokratia       Date:  2015 Jul-Sep       Impact factor: 0.471

7.  Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours.

Authors:  David R Yates; Morgan Rouprêt; Sarah J Drouin; Marie Audouin; Géraldine Cancel-Tassin; Eva Comperat; Marc-Olivier Bitker; Olivier Cussenot
Journal:  World J Urol       Date:  2012-09-28       Impact factor: 4.226

8.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Relationship of EMAST and microsatellite instability among patients with rectal cancer.

Authors:  Bikash Devaraj; Aaron Lee; Betty L Cabrera; Katsumi Miyai; Linda Luo; Sonia Ramamoorthy; Temitope Keku; Robert S Sandler; Kathleen L McGuire; John M Carethers
Journal:  J Gastrointest Surg       Date:  2010-09-16       Impact factor: 3.452

10.  Clinical significance of microsatellite instability in sporadic epithelial ovarian tumors.

Authors:  Bo-Sung Yoon; Young-Tae Kim; Jae-Hoon Kim; Sang-Wun Kim; Eun-Ji Nam; Nam-Hoon Cho; Jae-Wook Kim; Sunghoon Kim
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.